Key Highlights
- UNH shares gained 1.5% during Monday’s session, reaching an intraday peak of $283.30 and settling at $281.46.
- CMS finalized the 2027 Medicare Advantage payment rate at 2.48%, a substantial improvement from the 0.09% preliminary figure released in January.
- The revised rate will deliver approximately $13 billion in incremental government funding to health insurers during the upcoming year.
- Raymond James elevated UNH to “outperform” from “market perform” before the April 21 Q1 earnings release, establishing a $330 price objective.
- Humana shares soared 11% in premarket activity following the Medicare announcement; UNH and CVS Health each advanced over 6% before market open.
UNH began Monday’s trading at $277.26 and climbed to $283.30 during the session, finishing at $281.46 — representing a 1.5% increase.
UnitedHealth Group Incorporated, UNH
The equity has declined approximately 22% during the past half-year period and remains positioned beneath both its 50-day moving average of $283.03 and its 200-day moving average of $319.62. Wall Street analysts maintain a consensus price objective of $363.38.
Following the conclusion of Monday’s trading session, the Centers for Medicare and Medicaid Services (CMS) unveiled its final 2027 reimbursement rate for Medicare Advantage programs. The rate established a 2.48% average increase — a considerable improvement over the 0.09% preliminary rate announced in January, which had created significant concern throughout the healthcare insurance sector.
The January preliminary figure had pushed UNH and Humana shares downward upon its release. Market participants had been monitoring the situation closely for any positive revision in the final determination.
The enhanced rate equates to approximately $13 billion in supplementary reimbursements flowing to insurance companies during the next fiscal year. UNH and CVS Health, the parent organization of Aetna, experienced premarket gains exceeding 6% following the official announcement. Humana registered an 11% premarket advance.
Medicare Advantage: A Critical Revenue Component
Medicare Advantage represents the privately administered option to conventional Medicare and provides coverage for approximately 35 million beneficiaries during the current year, according to health research organization KFF. Participation has expanded consistently and currently surpasses traditional Medicare enrollment.
For insurance providers like UnitedHealth, this program serves as a fundamental revenue source. A minimal rate adjustment — while medical expenditures rise between 7% and 9% annually — had essentially functioned as a reduction, according to the Better Medicare Alliance.
Mizuho analyst Jared Holz characterized the 2.48% final rate as “certainly better than the government’s initial rate decision,” noting that it establishes an opportunity for margin expansion during the coming year if organizations maintain their focus on benefit optimization and cost alignment.
TD Cowen’s Ryan Langston had anticipated a more conservative adjustment within the 1% to 1.5% range, making the final figure a positive surprise relative to certain forecasts.
Bipartisan political attention had introduced uncertainty into the rate determination process. Members of both major political parties have expressed concerns regarding insurers receiving elevated payments through coded diagnoses — a methodology referred to as risk adjustment. The Biden administration initiated measures to restrict those practices, while the Trump administration’s January preliminary proposal indicated ongoing regulatory attention.
Q1 Earnings Report Scheduled for April 21
Raymond James elevated UNH from “market perform” to “outperform” on April 1, establishing a $330 price objective. The firm highlighted potential for leadership to demonstrate operational stabilization heading into the earnings announcement.
Barclays maintains an “overweight” designation with a $327 target. Mizuho and Leerink Partners similarly assign it “outperform” ratings, with price objectives of $350 and $345 respectively.
Among 28 analysts providing coverage for the stock, 18 assign a Buy recommendation, seven maintain a Hold stance, and two advise a Sell. The MarketBeat consensus rating stands at Moderate Buy.
First quarter financial results are scheduled for release on April 21. During Q4, UNH reported earnings of $2.11 per share, surpassing the consensus projection of $2.09. Revenue totaled $113.73 billion, representing a 12.3% year-over-year increase. Management has provided FY2026 EPS guidance of $17.75.
UNH distributes a quarterly dividend of $2.21, yielding approximately 3.1% annually based on current share prices.
Institutional investors hold 87.86% of outstanding shares, with recent position increases from Norges Bank, Berkshire Hathaway, and T. Rowe Price.
